Andrew Ryscavage is CEO of Brinton Bio. He advises private equity value-creation teams and biopharma executives in complex, regulated environments—where leaders must translate scientific, technical, and organizational change into measurable performance improvement.

His work is designed for scrutiny: decision clarity early, workflow-first redesign (not tool-first), minimum-viable governance that actually runs, and AI/automation applied only where it reduces cycle time, rework, or cost-to-serve.

Brinton Bio’s repeatable motion is simple: establish a decision-grade baseline, select 1–2 “unlock moves,” prove KPI shift in 60–90 days, then scale through the right Build–Buy–Partner path. Engagements leave behind an “Operational Truth Set”—baselines, decision logic, governance cadence, requirements/SOP drafts, KPI definitions, and a handoff plan internal teams can run.

Andrew’s background spans biomedical research and regulated transformation work across life sciences. He’s often brought in when strategy is obvious but execution is not—when the “AI story” is assumed, but not real—and leaders need a plan that converts ambition into durable operating performance.